XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.32M | 2.41M | 2.39M | 2.35M | 2.40M |
| Depreciation & Amortization | 117.10K | 115.40K | 106.00K | 105.00K | 139.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.62M | 2.84M | 3.34M | 3.90M | 4.96M |
| Operating Income | -2.62M | -2.84M | -3.34M | -3.90M | -4.96M |
| Income Before Tax | -3.31M | -736.60K | -1.48M | -3.35M | -2.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.31 | -0.74 | -1.48 | -3.35 | -2.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.31M | -736.60K | -1.48M | -3.35M | -2.16M |
| EBIT | -2.62M | -2.84M | -3.34M | -3.90M | -4.96M |
| EBITDA | -2.90M | -2.76M | -3.25M | -3.83M | -4.83M |
| EPS Basic | -1.35 | -0.04 | -0.50 | -1.41 | -1.11 |
| Normalized Basic EPS | -0.84 | -0.02 | -0.31 | -0.88 | -0.70 |
| EPS Diluted | -1.35 | -0.04 | -0.50 | -1.41 | -1.12 |
| Normalized Diluted EPS | -0.84 | -0.02 | -0.31 | -0.88 | -0.70 |
| Average Basic Shares Outstanding | 11.51M | 10.24M | 9.33M | 8.43M | 7.93M |
| Average Diluted Shares Outstanding | 11.51M | 10.24M | 9.33M | 8.43M | 7.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
